# Supplementation With Alpha-lipoic Acid and Silybum Marianum(LUDLEV®) for the Improvement of Fatty Liver Disease

> **NCT05913986** · NA · UNKNOWN · sponsor: **Saluz Investigación S. C.** · enrollment: 50 (estimated)

## Conditions studied

- Metabolic Associated Fatty Liver Disease

## Interventions

- **DIETARY_SUPPLEMENT:** LUDLEV®300 mg/46.2 mg
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05913986
- **Lead sponsor:** Saluz Investigación S. C.
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-03-01
- **Primary completion:** 2024-01-10
- **Final completion:** 2024-03-30
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2023-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05913986

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05913986, "Supplementation With Alpha-lipoic Acid and Silybum Marianum(LUDLEV®) for the Improvement of Fatty Liver Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05913986. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*